13 bans, 0 clarity: The legal quagmire denying miscarriage care

Four years after the U.S. Supreme Court’s Dobbs decision eliminated the constitutional right to abortion, miscarriage management remains a legal and clinical quagmire. The case of Mylissa McNeill powerfully illustrates the human cost: in August 2022, at 18 weeks pregnant with a nonviable pregnancy, she was denied a dilation and curettage (D&C) in Missouri (where an abortion ban had just taken effect) and even in Kansas, where abortion remained legal, because fetal cardiac activity was still detectable. For three days she bled and ached before finally receiving care in Illinois. McNeill now suffers from persistent health problems she attributes to that delay. Her story is not unique; it reflects a systemic failure driven by statutory language that leaves providers terrified of prosecution if they intervene while any fetal heart activity is present—even in doomed pregnancies. Across 13 states that currently enforce near-total abortion bans, exceptions to protect the pregnant woman’s life or health are often so vague that doctors and hospital legal teams err on the side of extreme caution. Although Missouri voters overturned its ban in 2024, similar ambiguous language persists elsewhere, and the chilling effect has not dissipated. Lawsuits in multiple states argue that the lack of clear definitions for ‘life-threatening’ or ‘health of the mother’ exceptions violates due process and endangers patients. The American College of Obstetricians and Gynecologists and other medical bodies warn that such barriers to standard-of-care miscarriage treatment—ranging from medication management to surgical evacuation—lead to preventable sepsis, hemorrhage, and loss of fertility. From a clinical standpoint, a miscarriage at 18 weeks where membranes have ruptured presents a high risk of infection; any delay in evacuation can be lethal. Yet hospitals, fearing criminal penalties or loss of licensure, have in numerous documented cases refused to act until the patient’s condition becomes undeniably emergent—often after severe deterioration. This creates an ethically untenable practice of ‘waiting for a crash.’ The economic and operational impact on healthcare systems is also significant: longer ICU stays, increased liability exposure, and resource drain from defensive medicine. Since Dobbs, emergency departments have seen a measurable shift in triage patterns for early pregnancy complications, with some facilities transferring patients to other states, further delaying care. Looking forward, the impasse will likely be resolved only through a combination of legislative clarification, state court rulings, or federal regulatory action—perhaps through the Emergency Medical Treatment and Labor Act (EMTALA)—that expressly defines miscarriage management as emergency care that cannot be withheld. In the interim, the muddled legal landscape continues to exact a heavy toll on women’s health, and the biopharma and medtech sectors face uncertainty about the markets for miscarriage management products in restrictive states. The story of Mylissa McNeill, playing out four years after the Dobbs ruling, underscores that the consequences of poorly drafted abortion bans extend far beyond elective abortion, bleeding into the fundamental right to receive emergency, life-preserving obstetric care.